All In Biotech

Drug Trial Radar · NCT03008187

MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia

A Phase I/II Study of SEL24 in Patients With Acute Myeloid Leukemia

Last checked: Nov 19, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

73

Actual

Start

Mar 10, 2017

Primary completion

Apr 13, 2023

Study completion Apr 13, 2023

Sponsor

Lead sponsor
Menarini GroupIndustry
Sponsor type
Industry
Collaborators
Medpace, Inc.; Theradex
First posted
Jan 2, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the clinical trial is to identify the maximum tolerated dose of MEN1703 and to further investigate its safety profile in participants with acute myeloid leukemia (AML).

Conditions

  • Acute Myeloid Leukemia

Interventions

  • MEN1703Drug

    MEN1703 given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 and Part 2: Number of Participants Experiencing Treatment-emergent Adverse EventsTime frame: Up to 21 months
  2. Part 1: Number of Participants Experiencing Dose-limiting Toxicity (DLT)Time frame: Day 1 through Day 21 (first treatment cycle)

Locations

15 sites in 4 countries. Site status is shown where the registry gives one.

  • Northside Hospital

    Atlanta, Georgia

  • Cleveland Clinic, Taussig Cancer Institute

    Cleveland, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Vanderbilt Ingram Cancer Center

    Nashville, Tennessee

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

    Meldola, Italy

  • Istituto Clinico Humanitas

    Milan, Italy

  • ASST Monza - Ospedale San Gerardo

    Monza, Italy

  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Oddzial Hematologii z Pododdzialem Chemioterapi

    Lodz, Poland

  • Institute of Haematology and Blood Transfusion

    Warsaw, Poland

  • Institut Català d'Oncologia

    Badalona, Spain

  • Hospital 12 de Octubre

    Madrid, Spain

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.